Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
Radezolid is a novel biaryloxazolidinone in clinical development which shows improved activity, including against linezolid-resistant strains. In a companion paper (29), we showed that radezolid accumulates about 11-fold in phagocytic cells, with approximately 60% of the drug localized in the cytosol and approximately 40% in the lysosomes of the cells. The present study examines its activity against (i) bacteria infecting human THP-1 macrophages and located in different subcellular compartments (Listeria monocytogenes, cytosol; Legionella pneumophila, vacuoles; Staphylococcus aureus and Staphylococcus epidermidis, mainly phagolysosomal), (ii) strains of S. aureus with clinically relevant mechanisms of resistance, and (iii) isogenic linezolid-susceptible and -resistant S. aureus strains infecting a series of phagocytic and nonphagocytic cells. Radezolid accumulated to similar levels ( approximately 10-fold) in all cell types (human keratinocytes, endothelial cells, bronchial epithelial cells, osteoblasts, macrophages, and rat embryo fibroblasts). At equivalent weight concentrations, radezolid proved consistently 10-fold more potent than linezolid in all these models, irrespective of the bacterial species and resistance phenotype or of the cell type infected. This results from its higher intrinsic activity and higher cellular accumulation. Time kill curves showed that radezolid's activity was more rapid than that of linezolid both in broth and in infected macrophages. These data suggest the potential interest of radezolid for recurrent or persistent infections where intracellular foci play a determinant role.
Lemaire
Sandrine
S
Unité de Pharmacologie Cellulaire et Moléculaire and Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
Kosowska-Shick
Klaudia
K
Appelbaum
Peter C
PC
Verween
Gunther
G
Tulkens
Paul M
PM
Van Bambeke
Françoise
F
D000081:Acetamides / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D006801:Humans; D016952:Legionella pneumophila / Q000187:drug effects*; D000069349:Linezolid; D008089:Listeria monocytogenes / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000008:administration & dosage / Q000494:pharmacology*; D010586:Phagocytes / Q000187:drug effects* / Q000382:microbiology*; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; C552047:radezolid; D000069349:Linezolid
Microb Pathog. 2003 Oct;35(4):159-68
12946328
Trends Microbiol. 2009 Feb;17(2):59-65
19208480
Nat Rev Microbiol. 2009 May;7(5):355-66
19369951
Nat Rev Microbiol. 2009 Jan;7(1):13-24
19011659
J Infect Dis. 2000 Apr;181(4):1337-49
10762565
Antimicrob Agents Chemother. 2009 Sep;53(9):3734-43
19564365
J Med Microbiol. 2007 Oct;56(Pt 10):1290-1295
17893163
Microbes Infect. 2007 Aug;9(10):1167-75
17761447
J Antimicrob Chemother. 2007 Feb;59(2):246-53
17220162
Thromb Haemost. 2005 Aug;94(2):266-77
16113815
J Cell Biol. 1974 Nov;63(2 Pt 1):383-401
4371790
Cell Microbiol. 2006 Nov;8(11):1720-9
16939532
Clin Microbiol Infect. 2008 Aug;14(8):766-77
18727801
Trends Microbiol. 2000 Aug;8(8):341-3
10920387
J Infect Dis. 2009 Nov 1;200(9):1367-70
19817587
Microbes Infect. 2004 Jan;6(1):129-39
14738901
Eur Respir J. 1998 May;11(5):1043-52
9648953
Int J Tissue React. 1994;16(5-6):211-20
7558665
Curr Opin Drug Discov Devel. 2006 Mar;9(2):218-30
16566292
Nat Rev Microbiol. 2009 Sep;7(9):623-8
19648949
Int J Cancer. 1980 Aug;26(2):171-6
6970727
Antimicrob Agents Chemother. 1990 Jun;34(6):1056-60
2168141
Antimicrob Agents Chemother. 2010 Jun;54(6):2540-8
20385873
Infect Immun. 2000 Sep;68(9):5385-92
10948168
J Cell Biol. 2002 Aug 5;158(3):409-14
12163465
Microb Pathog. 1999 Jun;26(6):317-23
10343060
Antimicrob Agents Chemother. 2006 Mar;50(3):841-51
16495241
Antimicrob Agents Chemother. 1987 Mar;31(3):410-6
3579258
J Antimicrob Chemother. 2009 Nov;64(5):1035-43
19759040
Med Microbiol Immunol. 2001 Sep;189(4):217-23
11599792
Cell. 1975 Nov;6(3):331-43
1052771
FEMS Immunol Med Microbiol. 2008 Oct;54(1):53-9
18625014
J Med Microbiol. 2007 Jan;56(Pt 1):83-93
17172522
Antimicrob Agents Chemother. 2008 Oct;52(10):3550-7
18663023
Antimicrob Agents Chemother. 2009 Jun;53(6):2289-97
19289525
Antimicrob Agents Chemother. 2008 Aug;52(8):2797-805
18519727
J Infect Dis. 2004 Jun 1;189(11):2101-9
15143479
Trends Microbiol. 2003 Feb;11(2):80-6
12598130
Proteomics. 2009 Dec;9(24):5484-96
19834917
Biochem Pharmacol. 1978 Feb 15;27(4):415-24
24449
Infect Immun. 2009 Sep;77(9):3611-25
19564384
Antimicrob Agents Chemother. 2006 Feb;50(2):765-9
16436741
Bioorg Med Chem Lett. 2008 Dec 1;18(23):6179-83
18951792
J Clin Microbiol. 1981 Dec;14(6):623-7
7037831
J Antimicrob Chemother. 2003 Apr;51(4):1051-2
12654747
Antimicrob Agents Chemother. 2003 Jul;47(7):2283-92
12821480
Antimicrob Agents Chemother. 2004 Aug;48(8):2853-60
15273091
J Infect Dis. 2005 Sep 15;192(6):1023-8
16107955
Cell Microbiol. 2003 Jun;5(6):417-26
12780779
J Antimicrob Chemother. 2005 Jun;55(6):897-904
15860552
Antimicrob Agents Chemother. 2008 May;52(5):1653-62
18316525
Antimicrob Agents Chemother. 2009 May;53(5):1874-83
19223616
PLoS One. 2008 Jan 09;3(1):e1409
18183290
Nat Rev Microbiol. 2005 Dec;3(12):948-58
16322743
Infect Dis Clin North Am. 2003 Sep;17(3):615-34
14711080
Microbes Infect. 2007 Aug;9(10):1188-95
17719818
J Bone Joint Surg Am. 2005 Jun;87(6):1343-7
15930546
Br J Dermatol. 2002 Jun;146(6):943-51
12072060